Summary. Background: Thrombocytopenia is the most common non-criteria hematological feature in patients with antiphospholipid syndrome (APS). This condition is more common in patients with catastrophic APS (CAPS). Objectives: To evaluate the prevalence of thrombocytopenia in a large series of high-risk patients with APS, and to assess the behavior of the platelet count during CAPS. Methods/Patients: This was a cross-sectional study in which we analyzed the platelet counts of a homogeneous group of high-risk APS patients (triplepositive). Six of these patients developed a catastrophic phase of the disease, and the platelet count was recorded before the acute phase, during the acute phase, and at recovery. Results: The mean platelet count in 119 highrisk triple-positive patients was 210 9 10 9 L
À1
. With a cut-off value for thrombocytopenia of 100 9 10 9 L
, the prevalence of thrombocytopenia was 6% (seven patients).
No difference between primary APS and secondary APS was found. In patients who suffered from CAPS, a [5] [6] [7] . Among the laboratory non-criteria of APS (features not included in the revised classification criteria for APS), thrombocytopenia is considered to be the most common [8] . It is usually mild (between 100 9 10 9 L À1 and 150 9 10 9 L À1 ) [9] and benign, and is rarely associated with bleeding complications. It does not require intervention [10, 11] , but it may pose a clinical problem, as the patient has to be treated with oral anticoagulants. APS patients may develop severe thrombocytopenia (< 30 9 10 9 L
) during the catastrophic phase [12] . Many studies have been published on the prevalence of thrombocytopenia in APS patients, and most of them have reported values between 20% and 53%, depending on the cut-off used (˂ 100 9 10 9 L À1 or ˂ 150 9 10 9 L À1 ) [13] , with different rates in patients with PAPS and SAPS [14, 15] . During the International Consensus on the classification criteria of the APS (2006 ISTH), a platelet count of 100 9 10 9 L À1 was proposed as the upper cut-off limit for thrombocytopenia in APS patients [2] .
To better understand the prevalence of thrombocytopenia, we analyzed a large homogeneous cohort of high-risk patients with primary or secondary APS, and the behavior of the platelet count during the catastrophic phase of APS.
Materials and methods
In this cross-sectional study, we evaluated the medical and laboratory records of 119 consecutive high-risk triple-positive APS patients followed at Padua Thrombosis Center in the last 20 years. Patient characteristics are shown in Table 1 . Forty-one patients were males and 78 were females, aged between 22 years to 80 years, with a mean age of 48 years. The prevalent isotype of aPL antibodies was IgG.
All of the patients had a history of arterial or venous thrombosis. The platelet count was evaluated with standard methods, and reported as the mean of three consecutive measurements. For each patient, the second platelet count was performed after 1 month from the index visit, and the third after 4-6 months. Platelet count was recorded during a follow-up visit after 6 months from the clinical event. aPL antibodies were measured as previously described [3, 16] . All of the patients were persistently positive for LAC, aCL and anti-b 2 GPI antibodies (triple-positive patients). Eighty-six had PAPS (no associated autoimmune disease) and 33 had SAPS (17 with systemic lupus erythematosus, nine with lupus-like syndrome, three with Sjogren syndrome, and four with other autoimmune diseases). Immune thrombocytopenia was diagnosed in two patients with severe thrombocytopenia. The platelet count was included in the study before the patients underwent splenectomy [17] .
Six patients (all with primary APS) with normal platelet counts later suffered from CAPS ( Table 2) ; one of these patients had two catastrophic episodes. Rapid-onset thromboses (usually within a week) with multiple smallvessel occlusions at various organs/systems typically occurred in all patients.
Statistics
Both the cut-off of 150 9 10 9 L
À1
and that of 100 9 10 9 L À1 were used to calculate the prevalence of thrombocytopenia. Mean and standard deviation were calculated for platelet counts in the entire group. For PAPS and SAPS patients, platelet counts were compared by use of the Mann-Whitney U-test for non-normally distributed values. Platelet counts during CAPS were compared by the use of Student's paired t-test. All analysis were performed with GRAPHPAD and IBM SPSS v. 24.
Results and discussion
The mean platelet count in 119 high-risk APS patients was 210 AE 72 9 10 9 L À1 (range 6 9 10 9 L À1 to 541 9 10 9 L À1 ). Mean platelet counts were 215 AE 73 9 10 9 L À1 in PAPS patients and 196 AE 67 9 10 9 L À1 in SAPS patients (Fig. 1) . The difference between groups was not statistically significant (mean difference 19; 95% confidence interval À 9 to 47). Eighteen patients (15.5%) had thrombocytopenia according to a threshold platelet count of 150 9 10 9 L
À1
; conversely, seven patients (6%) had thrombocytopenia according to a threshold platelet count of 100 9 10 9 L À1 .
The prevalence of thrombocytopenia was the same (15%) in PAPS and SAPS patients at a threshold of 150 9 10 9 L À1 . However, the prevalence of thrombocy- statistically significant risk factors for thrombocytopenia (both cut-offs) were found. Six patients with an average platelet count of 212 AE 51 9 10 9 L À1 in the quiescent phase suffered from a catastrophic event (Table 2) . One of these patients had two catastrophic episodes. Before the diagnosis, a progressive decrease in platelet count was observed, with a minimum at the time of the full clinical picture. The number of platelets began to decrease a few days before the onset of signs of the catastrophic event. On the day of diagnosis (Fig. 2) , 100% of the patients showed thrombocytopenia, with a mean platelet count of 60 AE 33 9 10 9 L
. The number of platelets continued to decrease for a few days, reaching a minimum average value of 42 AE 30 9 10 9 L
, and then slowly returned to a mean value of 220 AE 57 9 10 9 L À1 at the time of remission, with an overlapping trend in all of the patients. A platelet count of < 100 9 10 9 L À1 is generally considered to represent thrombocytopenia (moderate thrombocytopenia) [18] . This study considered the platelet count at a quiescent stage of a homogeneous group of high-risk APS patients with a full aPL antibody profile (triple positivity). The prevalence of thrombocytopenia (< 100 9 10 9 L À1 ) was low (6%), and was more common in PAPS patients (7%) than in SAPS patients (3%). Recently, the Euro-Phospholipid project [19] reported data on 1000 APS patients, and found that 29.6% of patients had thrombocytopenia (˂ 100 9 10 9 L
). The rate in PAPS patients was 21%, and that in SAPS patients was 41.9%. However, some studies have shown that the prevalences of thrombocytopenia in patients with PAPS or SAPS are similar [10, 20] . Differences in the aPL antibody profiles of the studied cohorts may account for these results. Although APS investigators have recently suggested that thrombocytopenia should be incorporated into the laboratory criteria of APS [13] , we have not found thrombocytopenia to be associated with APS, at least in triple-positive patients at high risk of recurrent thromboembolic events. Thrombocytopenia is more frequent in CAPS patients, having been detected in 65% of cases [6] . In our study, patients developing a catastrophic phase of the disease showed a significant progressive decrease in platelet count, starting a few days before the CAPS diagnosis, reaching a severe level (< 50 9 10 9 L À1 ) within a few days, and then returning slowly to the initial values.
An interesting observation is that thrombocytopenia in CAPS patients develops during the acute phase of the disease in patients previously showing a normal platelet count. This indicates direct involvement of platelets in this thrombotic microangiopathy [21] [22] [23] [24] , with consequent organ failure. Moreover, it is interesting to note that platelet counts decreased earlier before the full clinical picture of CAPS appeared. In other terms, a decrease in platelet count in APS patients should be considered as a warning signal for disease activity with possible progression to CAPS.
In conclusion, thrombocytopenia is not frequent in high-risk triple-positive APS patients, and there is no remarkable difference between PAPS and SAPS. Conversely, thrombocytopenia is the rule in patients with CAPS, and appears early, before the full picture and diagnosis of this feared complication of APS. 
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